Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma

doi:10.3748/wjg.v29.i10.1614

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5282)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-4) series.

Item

Count

PDF

243

WORD

HTML

2931

Figures (1-3)

351

Tables (1-4)

290

Sum=3861

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

159

Download

518

Sum=677

Publishing Process of This Article

Item

Count

Browse

172

Download

572

Sum=744

Mar 14, 2023 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (13)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Mar 14, 2023; 29(10): 1614-1626
Published online Mar 14, 2023. doi: 10.3748/wjg.v29.i10.1614

Table 2 Therapeutic efficacy in all patients, n (%)

	Lenvatinib + TACE + PD-1 (n = 45)	Lenvatinib + TACE (n = 20)	P value
CR	0 (0)	0 (0)
PR	20 (44.4)	4 (20)
SD	22 (48.9)	9 (45)
PD	3 (6.7)	7 (35)
ORR	20 (44.4)	4 (20)	0.059¹
DCR	42 (93.3)	13 (64)	0.003¹

¹χ² test.

²Fisher’s exact test.

BCLC: Barcelona Clinic Liver Cancer; DCR: Disease control rate; ORR: Objective response rate; PD: Progressive disease; PR: Partial response; SD: Stable disease; PD-1: Programmed death receptor-1; TACE: Transarterial chemoembolization.

Citation: Wang YY, Yang X, Wang YC, Long JY, Sun HS, Li YR, Xun ZY, Zhang N, Xue JN, Ning C, Zhang JW, Zhu CP, Zhang LH, Yang XB, Zhao HT. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma. World J Gastroenterol 2023; 29(10): 1614-1626
URL: https://www.wjgnet.com/1007-9327/full/v29/i10/1614.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i10.1614